AFX:XETRA-Carl Zeiss Meditec AG (EUR)

COMMON STOCK | Medical Instruments & Supplies | XETRA

Last Closing Price

EUR 91.45

Change

+4.15 (+4.75)%

Market Cap

EUR 7.94B

Volume

0.23M

Average Target Price

EUR 101.38 (+10.85%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-28 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTL:XETRA Baxter International Inc

+2.48 (+3.21%)

EUR40.08B 45.52 22.72
SRT3:XETRA Sartorius Aktiengesellschaft

+11.00 (+3.65%)

EUR19.86B 138.17 47.48
SRT:XETRA Sartorius Aktiengesellschaft

+15.00 (+5.73%)

EUR19.84B 126.14 47.48
GXI:XETRA Gerresheimer AG

+1.80 (+2.43%)

EUR2.38B 24.49 11.64

ETFs Containing AFX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.57% 25% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.57% 25% F 24% F
Trailing 12 Months  
Capital Gain 8.74% 25% F 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.74% 25% F 76% C
Trailing 5 Years  
Capital Gain 311.84% 50% F 98% A+
Dividend Return 8.56% 50% F 41% F
Total Return 320.40% 50% F 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 40.12% 50% F 96% A
Dividend Return 1.12% 50% F 38% F
Total Return 41.24% 50% F 96% A
Risk Return Profile  
Volatility (Standard Deviation) 15.43% 75% C 39% F
Risk Adjusted Return 267.28% 100% A+ 100% A+
Market Capitalization 7.94B 40% F 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 49.11 60% D- 16% F
Price/Book Ratio 5.57 80% B- 15% F
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA 27.55 60% D- 10% F
Management Effectiveness  
Return on Equity 11.87% 40% F 66% D
Return on Invested Capital 13.75% 60% D- 80% B-
Return on Assets 8.16% 60% D- 87% B+
Debt to Equity Ratio 7.80% 100% A+ 85% B
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.48 60% D- 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.